. . . . "Mycophenolic acid is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways, mycophenolic acid has potent cytostatic effects on lymphocytes. Mycophenolic acid inhibits proliferative responses of T- and B-lymphocytes to both mitogenic and allospecific stimulation. Addition of guanosine or deoxyguanosine reverses the cytostatic effects of mycophenolic acid on lymphocytes. Mycophenolic acid also suppresses antibody formation by B-lymphocytes. Mycophenolic acid prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection."@en . . . "(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid"@en . . " "@en . . . "# Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS: Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess. 2005 May;9(21):1-179, iii-iv. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15899149"@en . . . . . . . ">98%"@en . . . "Acide mycophenolique"@en . . . "Bioavailability following oral administration of Myfortic delayed-release tablet ranges from 70-95%"@en . "Mycophenolate"@en . . "Humans and other mammals"@en . "Mycophenolic acid"@en . . . . . . . . . "Acido micofenolico"@en . . . "* 140 +/- 30 mL/min [Stable renal transplant patients]"@en . . "Mycophenoic acid"@en . . . "Mycophenolsaeure"@en . "Bernard J. Abbott, John G. Whitney, \"Method of preparing mycophenolic acid glucoside.\" U.S. Patent US4234684, issued January, 1976."@en . "Micofenolico acido"@en . "The mean elimination half-life for mycophenolic acid ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours."@en . . "For the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids."@en . . "Oral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia."@en . . . . . . "Acidum mycophenolicum"@en . . . "24280-93-1"@en . . . . . . . . . "approved"@en . . "Mycophenolic acid is an an immunosuppresant drug and potent anti-proliferative, and can be used in place of the older anti-proliferative azathioprine. It is usually used as part of triple therapy including a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. It is also useful in research for the selection of animal cells that express the E. coli gene coding for XGPRT (xanthine guanine phosphoribosyltransferase)."@en . . "* 54 \u00B1 25 L"@en . . . . .